Drug facts
BrandDiscontinuedCelestone (Betamethasone)
No generic version of Celestone has an active Orange Book listing (a generic was first approved before 1982); no Celestone patent or exclusivity is listed in the Orange Book.
Celestone was first approved by the FDA before 1982 under NDA 017561; the application holder is Schering Corp Sub Schering Plough Corp.
The latest NADAC for CELESTONE SOLUSPAN 30 MG/5 ML is $8.80 per mL (as of 10/28/2026).
Holder Schering Corp Sub Schering Plough CorpApplication NDA 017561Approved before 1982
01Patents and exclusivity
When competition can legally begin. A generic can launch once both exclusivity and the last listed patent expire, unless a court or settlement says otherwise.
- Latest patent
- No Celestone patent listed in the Orange Book Orange Book
02Competition
- Generics
- No active generic listing in the Orange Book Orange Book
- First generic approved
- before 1982 Orange Book
Every listingEach listing and maker behind the generics count.
Price erosionHow NADAC moves as generics enter.
PrescribersWho prescribes it, from Medicare data.
Available in the full Celestone profile.See what is included
03Supply and price
- FDA drug shortage
- ClearNot on the current shortage list FDA shortages
- NADAC
- $8.80 per mLCELESTONE SOLUSPAN 30 MG/5 ML, as of 10/28/2026 CMS NADAC
- Latest recall
- 04/13/2022Class II, Celestone Soluspan, Mckesson Medical-Surgical Inc. Corporate Office FDA enforcement
04Product
- Application holder
- Schering Corp Sub Schering Plough Corp Orange Book
- Application
- NDA 017561 Orange Book
- First approved
- before 1982 Orange Book
- Dosage forms
- injectable
- Routes
- injection
- Status
- Discontinued
Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.